Influence  	Influence  	 NN	O
of  	of  	 IN	O
adding  	adding  	 VBG	B-NP
etravirine  	etravirine  	 NN	I-NP
on  	on  	 IN	O
complexity  	complexity  	 JJ	B-NP
index  	index  	 NN	I-NP
and  	and  	 CC	O
patients 	patients 	 NNS	O
'  	'  	 POS	O
perceived  	perceived  	 JJ	O
complexity  	complexity  	 NN	B-NP
Adherence  	Adherence  	 NNS	I-NP
to  	to  	 TO	O
highly  	highly  	 RB	B-NP
active  	active  	 JJ	I-NP
antiretroviral  	antiretroviral  	 JJ	I-NP
treatment  	treatment  	 NN	O
( 	( 	 -LRB-	O
HAART 	HAART 	 NNP	B-NP
)  	)  	 -RRB-	O
is  	is  	 VBZ	O
an  	an  	 DT	O
important  	important  	 JJ	O
predictive  	predictive  	 JJ	B-NP
factor  	factor  	 NN	I-NP
of  	of  	 IN	I-NP
treatment  	treatment  	 NN	I-NP
outcome 	outcome 	 NN	I-NP
.  	.  	 .	O
Medication  	Medication  	 JJ	B-NP
regimen  	regimen  	 JJ	I-NP
complexity  	complexity  	 NN	I-NP
can  	can  	 MD	O
be  	be  	 VB	O
one  	one  	 CD	O
of  	of  	 IN	O
the  	the  	 DT	O
main  	main  	 JJ	O
causes  	causes  	 NNS	O
of  	of  	 IN	O
non-adherence 	non-adherence 	 JJ	B-NP
.  	.  	 .	O
Thus 	Thus 	 RB	O
,  	,  	 ,	O
treatment  	treatment  	 NN	B-NP
simplification  	simplification  	 NN	I-NP
is  	is  	 VBZ	O
a  	a  	 DT	O
key  	key  	 JJ	B-NP
strategy  	strategy  	 NN	I-NP
in  	in  	 IN	O
the  	the  	 DT	O
development  	development  	 NN	O
of  	of  	 IN	O
antiretroviral  	antiretroviral  	 JJ	B-NP
therapy 	therapy 	 NN	I-NP
.  	.  	 .	O
The  	The  	 DT	O
aim  	aim  	 NN	O
of  	of  	 IN	O
this  	this  	 DT	O
study  	study  	 NN	O
was  	was  	 VBD	O
to  	to  	 TO	O
determine  	determine  	 VB	O
the  	the  	 DT	O
influence  	influence  	 NN	O
of  	of  	 IN	O
adding  	adding  	 VBG	B-NP
etravirine  	etravirine  	 NN	I-NP
on  	on  	 IN	O
complexity  	complexity  	 JJ	B-NP
index  	index  	 NN	I-NP
and  	and  	 CC	O
patients 	patients 	 NNS	O
'  	'  	 POS	O
perceived  	perceived  	 JJ	O
complexity  	complexity  	 NN	O
of  	of  	 IN	O
their  	their  	 PRP$	O
treatment  	treatment  	 NN	B-NP
regimen 	regimen 	 NN	I-NP
.  	.  	 .	O
We  	We  	 PRP	O
conducted  	conducted  	 VBD	O
a  	a  	 DT	O
prospective  	prospective  	 JJ	B-NP
two-centre  	two-centre  	 JJ	I-NP
observational  	observational  	 JJ	I-NP
study 	study 	 NN	I-NP
.  	.  	 .	O
Patients  	Patients  	 NNS	O
on  	on  	 IN	O
etravirine-based  	etravirine-based  	 JJ	B-NP
therapy 	therapy 	 NN	I-NP
,  	,  	 ,	O
for  	for  	 IN	O
at  	at  	 IN	O
least  	least  	 JJS	O
6 months 	6 months 	 CD	O
,  	,  	 ,	O
who  	who  	 WP	O
came  	came  	 VBD	O
personally  	personally  	 RB	O
to  	to  	 TO	O
pharmacy  	pharmacy  	 VB	O
departments  	departments  	 NNS	O
for  	for  	 IN	O
a  	a  	 DT	O
drug  	drug  	 NN	B-NP
refill  	refill  	 NN	I-NP
from  	from  	 IN	O
February  	February  	 NNP	O
to  	to  	 TO	O
July  	July  	 NNP	O
2012  	2012  	 CD	O
were  	were  	 VBD	O
included 	included 	 VBN	O
.  	.  	 .	O
Data  	Data  	 NNP	O
were  	were  	 VBD	O
collected  	collected  	 VBN	O
for  	for  	 IN	O
the  	the  	 DT	O
current  	current  	 JJ	O
etravirine-based  	etravirine-based  	 JJ	B-NP
HAART  	HAART  	 NNP	I-NP
and  	and  	 CC	O
for  	for  	 IN	O
the  	the  	 DT	O
previous  	previous  	 JJ	O
HAART  	HAART  	 NN	B-NP
without  	without  	 IN	O
etravirine 	etravirine 	 NN	B-NP
.  	.  	 .	O
The  	The  	 DT	O
main  	main  	 JJ	O
variables  	variables  	 NNS	O
were  	were  	 VBD	O
complexity  	complexity  	 JJ	B-NP
index  	index  	 NN	I-NP
and  	and  	 CC	O
patients 	patients 	 NNS	O
'  	'  	 POS	O
perceived  	perceived  	 JJ	O
complexity 	complexity 	 NN	O
.  	.  	 .	O
We  	We  	 PRP	O
also  	also  	 RB	O
evaluated  	evaluated  	 VBN	O
the  	the  	 DT	O
adherence  	adherence  	 NN	O
during  	during  	 IN	O
the  	the  	 DT	O
6 months  	6 months  	 NN	O
before  	before  	 IN	O
and  	and  	 CC	O
after  	after  	 IN	O
the  	the  	 DT	O
introduction  	introduction  	 NN	B-NP
of  	of  	 IN	I-NP
etravirine  	etravirine  	 NN	I-NP
into  	into  	 IN	O
HAART 	HAART 	 NNP	B-NP
.  	.  	 .	O
The  	The  	 DT	O
complexity  	complexity  	 NN	B-NP
index  	index  	 NN	I-NP
was  	was  	 VBD	O
based  	based  	 VBN	O
on  	on  	 IN	O
a  	a  	 DT	O
score  	score  	 NN	O
which  	which  	 WDT	O
takes  	takes  	 VBZ	O
into  	into  	 IN	O
account  	account  	 NN	O
the  	the  	 DT	O
number  	number  	 NN	O
of  	of  	 IN	O
pills  	pills  	 NNS	O
per  	per  	 IN	O
day 	day 	 NN	O
,  	,  	 ,	O
the  	the  	 DT	O
dosing  	dosing  	 JJ	O
schedule 	schedule 	 NN	O
,  	,  	 ,	O
the  	the  	 DT	O
dosage  	dosage  	 JJ	B-NP
form  	form  	 NN	I-NP
and  	and  	 CC	O
any  	any  	 DT	O
specific  	specific  	 JJ	O
instructions  	instructions  	 NNS	B-NP
linked  	linked  	 VBN	O
to  	to  	 TO	O
use  	use  	 VB	O
of  	of  	 IN	O
the  	the  	 DT	O
drug 	drug 	 NN	O
.  	.  	 .	O
To  	To  	 TO	O
evaluate  	evaluate  	 VB	O
the  	the  	 DT	O
patients 	patients 	 NNS	O
'  	'  	 POS	O
perceived  	perceived  	 JJ	O
complexity  	complexity  	 NN	O
of  	of  	 IN	O
their  	their  	 PRP$	O
current  	current  	 JJ	O
and  	and  	 CC	O
previous  	previous  	 JJ	O
HAART 	HAART 	 NNP	B-NP
,  	,  	 ,	O
patients  	patients  	 NNS	O
were  	were  	 VBD	O
asked  	asked  	 VBN	O
to  	to  	 TO	O
assign  	assign  	 VB	O
a  	a  	 DT	O
mark  	mark  	 NN	O
on  	on  	 IN	O
a  	a  	 DT	O
visual  	visual  	 JJ	O
analogue  	analogue  	 JJ	B-NP
scale  	scale  	 NN	I-NP
ranging  	ranging  	 VBG	O
from  	from  	 IN	O
0  	0  	 CD	O
( 	( 	 -LRB-	O
minimum 	minimum 	 NN	O
)  	)  	 -RRB-	O
to  	to  	 TO	O
10  	10  	 CD	O
( 	( 	 -LRB-	O
maximum 	maximum 	 NN	B-NP
) 	) 	 -RRB-	O
.  	.  	 .	O
We  	We  	 PRP	O
assessed  	assessed  	 VBD	O
the  	the  	 DT	O
differences  	differences  	 NNS	O
in  	in  	 IN	O
the  	the  	 DT	O
variables  	variables  	 NNS	O
collected  	collected  	 VBN	O
between  	between  	 IN	O
the  	the  	 DT	O
current  	current  	 JJ	O
and  	and  	 CC	O
previous  	previous  	 JJ	O
antiretroviral  	antiretroviral  	 JJ	B-NP
therapy 	therapy 	 NN	I-NP
.  	.  	 .	O
Finally 	Finally 	 RB	O
,  	,  	 ,	O
we  	we  	 PRP	O
carried  	carried  	 VBD	O
out  	out  	 RP	O
a  	a  	 DT	O
correlation  	correlation  	 JJ	B-NP
analysis  	analysis  	 NN	I-NP
between  	between  	 IN	O
the  	the  	 DT	O
complexity  	complexity  	 NN	B-NP
index  	index  	 NN	I-NP
and  	and  	 CC	O
the  	the  	 DT	O
patients 	patients 	 NNS	O
'  	'  	 POS	O
perceived  	perceived  	 JJ	O
complexity 	complexity 	 NN	O
.  	.  	 .	O
Eighty  	Eighty  	 JJ	O
patients  	patients  	 NNS	O
were  	were  	 VBD	O
included 	included 	 VBN	O
.  	.  	 .	O
The  	The  	 DT	O
complexity  	complexity  	 NN	B-NP
index  	index  	 NN	I-NP
was  	was  	 VBD	O
significantly  	significantly  	 RB	O
reduced  	reduced  	 VBN	O
after  	after  	 IN	O
the  	the  	 DT	O
addition  	addition  	 NN	B-NP
of  	of  	 IN	O
etravirine  	etravirine  	 VBG	O
to  	to  	 TO	O
HAART  	HAART  	 NNP	B-NP
( 	( 	 -LRB-	O
P = 0·035 	P = 0·035 	 NNP	O
) 	) 	 -RRB-	O
.  	.  	 .	O
Perceived  	Perceived  	 JJ	O
complexity  	complexity  	 NN	O
was  	was  	 VBD	O
also  	also  	 RB	O
reduced  	reduced  	 VBN	O
( 	( 	 -LRB-	O
P = 0·015 	P = 0·015 	 NNP	O
) 	) 	 -RRB-	O
.  	.  	 .	O
After  	After  	 IN	O
the  	the  	 DT	O
introduction  	introduction  	 NN	B-NP
of  	of  	 IN	O
the  	the  	 DT	O
drug 	drug 	 NN	O
,  	,  	 ,	O
the  	the  	 DT	O
proportion  	proportion  	 NN	O
of  	of  	 IN	O
adherent  	adherent  	 JJ	B-NP
patients  	patients  	 NNS	I-NP
increased  	increased  	 VBN	O
from  	from  	 IN	O
65 	65 	 CD	O
%  	%  	 NN	O
to  	to  	 TO	O
81·3 	81·3 	 CD	O
%  	%  	 NN	O
( 	( 	 -LRB-	O
P = 0·002 	P = 0·002 	 NNP	O
) 	) 	 -RRB-	O
.  	.  	 .	O
The  	The  	 DT	O
correlation  	correlation  	 NN	O
between  	between  	 IN	O
the  	the  	 DT	O
complexity  	complexity  	 NN	B-NP
index  	index  	 NN	I-NP
and  	and  	 CC	O
the  	the  	 DT	O
patients 	patients 	 NNS	O
'  	'  	 POS	O
perceived  	perceived  	 JJ	O
complexity  	complexity  	 NN	O
was  	was  	 VBD	O
positive  	positive  	 JJ	O
( 	( 	 -LRB-	O
r = 0·594 	r = 0·594 	 NNP	O
) 	) 	 -RRB-	O
.  	.  	 .	O
The  	The  	 DT	O
correlation  	correlation  	 NN	O
increased  	increased  	 VBD	O
( 	( 	 -LRB-	O
r = 0·696 	r = 0·696 	 NNP	O
)  	)  	 -RRB-	O
when  	when  	 WRB	O
the  	the  	 DT	O
difference  	difference  	 NN	O
between  	between  	 IN	O
the  	the  	 DT	O
complexity  	complexity  	 NN	B-NP
index  	index  	 NN	I-NP
before  	before  	 IN	O
and  	and  	 CC	O
after  	after  	 IN	O
the  	the  	 DT	O
introduction  	introduction  	 NN	B-NP
of  	of  	 IN	I-NP
etravirine  	etravirine  	 NN	I-NP
in  	in  	 IN	O
HAART  	HAART  	 NNP	B-NP
grew 	grew 	 VBD	O
.  	.  	 .	O
The  	The  	 DT	O
addition  	addition  	 NN	B-NP
of  	of  	 IN	O
etravirine  	etravirine  	 VBG	O
to  	to  	 TO	O
HAART  	HAART  	 NNP	B-NP
results  	results  	 NNS	I-NP
in  	in  	 IN	O
a  	a  	 DT	O
significant  	significant  	 JJ	O
reduction  	reduction  	 NN	O
in  	in  	 IN	O
complexity  	complexity  	 JJ	B-NP
index  	index  	 NN	I-NP
and  	and  	 CC	O
patients 	patients 	 NNS	O
'  	'  	 POS	O
perceived  	perceived  	 JJ	O
complexity  	complexity  	 NN	O
of  	of  	 IN	O
their  	their  	 PRP$	O
therapy 	therapy 	 NN	O
.  	.  	 .	O
These  	These  	 DT	O
changes  	changes  	 NNS	O
were  	were  	 VBD	O
associated  	associated  	 VBN	O
with  	with  	 IN	O
better  	better  	 JJR	O
adherence  	adherence  	 NN	O
to  	to  	 TO	O
treatment 	treatment 	 NN	O
.  	.  	 .	O
